Brief: Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib
10/12/2022 20:21
Dec 10 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS PRESENTS UPDATED INTERIM DATA FOR
ZILOVERTAMAB IN COMBINATION WITH IBRUTINIB AT ASH 2022
* ONCTERNAL THERAPEUTICS - UPDATED MCL AND CLL DATA FROM
ONGOING
PHASE 1/2 STUDY OF ZILOVERTAMAB AND IBRUTINIB ARE ENCOURAGING;
CONTINUE TO IMPROVE
* ORR OF 89% AND CR RATE OF 43% FOR PATIENTS WITH MCL
TREATED WITH
ZILOVERTAMAB PLUS IBRUTINIB
* ONCTERNAL THERAPEUTICS- LANDMARK PFS WAS 100% AT 42 MONTHS
FOR
PATIENTS WITH CLL EXPRESSING P53 MUTATION/DEL(17P) TREATED WITH
ZILOVERTAMAB PLUS IBRUTINIB
Source text for Eikon: ID:nGNXbd9NRZ
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;